Has Enrique Mendez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,924,496 in general payments to Enrique Mendez, MD across 1,642 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Enrique Mendez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Enrique Mendez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Enrique Mendez, MD

Rheumatology · Lake Charles, LANPI 1174605646

Payments from drug & device makers

$1,924,496in general payments, 2019–2025

Across 1,642 payments — averaging $1172.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$803K
UCB SA$366K
Novartis$247K
Amgen$146K
Sun Pharmaceutical Industries Inc.$103K
Argenx US, Inc.$74K
plus $187K from 37 others

$26,625in research payments, 2019–2025

Across 4 payments — averaging $6656.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$27K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	34	$802,739
UCB SA	20	$366,059
Novartis	49	$246,505
Amgen(2 entities)	292	$145,517
Sun Pharmaceutical Industries Inc.	137	$102,653
Argenx US, Inc.	61	$73,943
Astrazeneca UK Limited	3	$71,242
Idorsia Pharmaceuticals US Inc	13	$34,632
AbbVie(2 entities)	225	$29,997
Takeda Pharmaceuticals U.S.A., Inc.	6	$19,375
Kiniksa Pharmaceuticals, Ltd.	32	$12,853
ANI Pharmaceuticals, Inc.	72	$5,942
Mallinckrodt Hospital Products Inc.	106	$2,378
Johnson & Johnson	62	$1,335
GSK	60	$1,177
Pfizer	90	$1,172
AstraZeneca(2 entities)	46	$1,092
UCB, Inc.	54	$1,079
Aurinia Pharma U.S., Inc.	54	$950
E.r. Squibb & Sons, L.L.C.	64	$751
Lilly USA, LLC	36	$578
Sanofi	21	$560
Mallinckrodt Enterprises LLC	26	$528
Boehringer Ingelheim	11	$231
Medexus Pharma, Inc.	23	$202
Daiichi Sankyo Inc.	10	$130
Genentech USA, Inc.	7	$122
Novo Nordisk	2	$113
Sanofi-aventis U.S. LLC	1	$100
Janssen Scientific Affairs, LLC	2	$91
Fresenius Kabi USA, LLC	3	$61
Zyla Life Sciences, Inc.	3	$53
Antares Pharma, Inc.	3	$48
Bristol Myers Squibb	2	$44
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$44
Radius Health, Inc.	2	$43
Scilex Pharmaceuticals Inc.	1	$42
Ultragenyx Pharmaceutical Inc.	2	$34
Pacira Therapeutics, Inc.	1	$21
Collegium Pharmaceutical, Inc.	1	$20
Teva Pharmaceuticals USA, Inc.	1	$15
Regeneron Healthcare Solutions, Inc.	1	$15
Emergent Biosolutions Inc.	1	$13

How this compares

$1,924,496 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$1,669,186

Medicare patients

890

Services billed

100,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Lake Charles

Gurjot BasraLake Charles$166K
Stephen LindseyBaton Rouge$3.6M
Aaron BroadwellShreveport$1.7M
Saravanan ThiagarajanBaton Rouge$1.2M
Jyothi MallepalliMonroe$998K
Lesley SaketkooNew Orleans$294K
William DavisNew Orleans$288K
Ladislas LazaroLafayette$265K
Jerry PoundsMetairie$252K
Carl GauthierHammond$219K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →